vs

Side-by-side financial comparison of West Pharmaceutical Services (WST) and Western Union CO (WU). Click either name above to swap in a different company.

Western Union CO is the larger business by last-quarter revenue ($982.7M vs $805.0M, roughly 1.2× West Pharmaceutical Services). West Pharmaceutical Services runs the higher net margin — 16.4% vs 6.6%, a 9.8% gap on every dollar of revenue. On growth, West Pharmaceutical Services posted the faster year-over-year revenue change (7.5% vs 0.0%). Over the past eight quarters, West Pharmaceutical Services's revenue compounded faster (7.6% CAGR vs -1.9%).

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.

The Western Union Company is an American multinational financial services corporation headquartered in Denver, Colorado.

WST vs WU — Head-to-Head

Bigger by revenue
WU
WU
1.2× larger
WU
$982.7M
$805.0M
WST
Growing faster (revenue YoY)
WST
WST
+7.5% gap
WST
7.5%
0.0%
WU
Higher net margin
WST
WST
9.8% more per $
WST
16.4%
6.6%
WU
Faster 2-yr revenue CAGR
WST
WST
Annualised
WST
7.6%
-1.9%
WU

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
WST
WST
WU
WU
Revenue
$805.0M
$982.7M
Net Profit
$132.1M
$64.7M
Gross Margin
37.8%
Operating Margin
19.5%
12.5%
Net Margin
16.4%
6.6%
Revenue YoY
7.5%
0.0%
Net Profit YoY
1.5%
-47.6%
EPS (diluted)
$1.82
$0.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
WST
WST
WU
WU
Q1 26
$982.7M
Q4 25
$805.0M
$972.0M
Q3 25
$804.6M
$985.3M
Q2 25
$766.5M
$983.6M
Q1 25
$698.0M
$938.7M
Q4 24
$748.8M
$1.0B
Q3 24
$746.9M
$993.4M
Q2 24
$702.1M
$1.0B
Net Profit
WST
WST
WU
WU
Q1 26
$64.7M
Q4 25
$132.1M
$114.4M
Q3 25
$140.0M
$139.6M
Q2 25
$131.8M
$122.1M
Q1 25
$89.8M
$123.5M
Q4 24
$130.1M
$385.7M
Q3 24
$136.0M
$264.8M
Q2 24
$111.3M
$141.0M
Gross Margin
WST
WST
WU
WU
Q1 26
Q4 25
37.8%
33.6%
Q3 25
36.6%
34.7%
Q2 25
35.7%
34.6%
Q1 25
33.2%
34.0%
Q4 24
36.5%
35.0%
Q3 24
35.4%
34.2%
Q2 24
32.8%
35.0%
Operating Margin
WST
WST
WU
WU
Q1 26
12.5%
Q4 25
19.5%
19.1%
Q3 25
20.8%
20.5%
Q2 25
20.1%
19.6%
Q1 25
15.3%
18.9%
Q4 24
21.3%
17.5%
Q3 24
21.6%
16.6%
Q2 24
18.0%
18.7%
Net Margin
WST
WST
WU
WU
Q1 26
6.6%
Q4 25
16.4%
11.8%
Q3 25
17.4%
14.2%
Q2 25
17.2%
12.4%
Q1 25
12.9%
13.2%
Q4 24
17.4%
37.9%
Q3 24
18.2%
26.7%
Q2 24
15.9%
13.8%
EPS (diluted)
WST
WST
WU
WU
Q1 26
$0.41
Q4 25
$1.82
$0.36
Q3 25
$1.92
$0.43
Q2 25
$1.82
$0.37
Q1 25
$1.23
$0.36
Q4 24
$1.78
$1.14
Q3 24
$1.85
$0.78
Q2 24
$1.51
$0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
WST
WST
WU
WU
Cash + ST InvestmentsLiquidity on hand
$791.3M
$909.2M
Total DebtLower is stronger
$202.8M
Stockholders' EquityBook value
$3.2B
$910.5M
Total Assets
$4.3B
$8.1B
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
WST
WST
WU
WU
Q1 26
$909.2M
Q4 25
$791.3M
$1.2B
Q3 25
$628.5M
$947.8M
Q2 25
$509.7M
$1.0B
Q1 25
$404.2M
$1.3B
Q4 24
$484.6M
$1.5B
Q3 24
$490.9M
$1.1B
Q2 24
$446.2M
$1.0B
Total Debt
WST
WST
WU
WU
Q1 26
Q4 25
$202.8M
$2.9B
Q3 25
$202.7M
$2.5B
Q2 25
$202.6M
$2.5B
Q1 25
$202.6M
$2.5B
Q4 24
$202.6M
$3.0B
Q3 24
$202.6M
$2.1B
Q2 24
$205.8M
$2.1B
Stockholders' Equity
WST
WST
WU
WU
Q1 26
$910.5M
Q4 25
$3.2B
$957.8M
Q3 25
$3.1B
$925.4M
Q2 25
$2.9B
$883.6M
Q1 25
$2.7B
$939.4M
Q4 24
$2.7B
$968.9M
Q3 24
$2.8B
$652.7M
Q2 24
$2.6B
$440.8M
Total Assets
WST
WST
WU
WU
Q1 26
$8.1B
Q4 25
$4.3B
$8.3B
Q3 25
$4.1B
$7.8B
Q2 25
$4.0B
$8.0B
Q1 25
$3.6B
$8.3B
Q4 24
$3.6B
$8.4B
Q3 24
$3.7B
$7.7B
Q2 24
$3.5B
$8.0B
Debt / Equity
WST
WST
WU
WU
Q1 26
Q4 25
0.06×
3.01×
Q3 25
0.07×
2.70×
Q2 25
0.07×
2.83×
Q1 25
0.08×
2.61×
Q4 24
0.08×
3.04×
Q3 24
0.07×
3.29×
Q2 24
0.08×
4.88×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
WST
WST
WU
WU
Operating Cash FlowLast quarter
$251.1M
$109.0M
Free Cash FlowOCF − Capex
$175.0M
FCF MarginFCF / Revenue
21.7%
Capex IntensityCapex / Revenue
9.5%
4.8%
Cash ConversionOCF / Net Profit
1.90×
1.68×
TTM Free Cash FlowTrailing 4 quarters
$468.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
WST
WST
WU
WU
Q1 26
$109.0M
Q4 25
$251.1M
$135.4M
Q3 25
$197.2M
$260.4M
Q2 25
$177.1M
$-300.0K
Q1 25
$129.4M
$148.2M
Q4 24
$190.1M
$134.0M
Q3 24
$180.1M
$212.1M
Q2 24
$165.0M
$-33.8M
Free Cash Flow
WST
WST
WU
WU
Q1 26
Q4 25
$175.0M
$115.5M
Q3 25
$133.9M
$252.7M
Q2 25
$101.9M
$-7.8M
Q1 25
$58.1M
$144.8M
Q4 24
$85.2M
$119.7M
Q3 24
$98.8M
$205.1M
Q2 24
$64.8M
$-38.9M
FCF Margin
WST
WST
WU
WU
Q1 26
Q4 25
21.7%
11.9%
Q3 25
16.6%
25.6%
Q2 25
13.3%
-0.8%
Q1 25
8.3%
15.4%
Q4 24
11.4%
11.8%
Q3 24
13.2%
20.6%
Q2 24
9.2%
-3.8%
Capex Intensity
WST
WST
WU
WU
Q1 26
4.8%
Q4 25
9.5%
2.0%
Q3 25
7.9%
0.8%
Q2 25
9.8%
0.8%
Q1 25
10.2%
0.4%
Q4 24
14.0%
1.4%
Q3 24
10.9%
0.7%
Q2 24
14.3%
0.5%
Cash Conversion
WST
WST
WU
WU
Q1 26
1.68×
Q4 25
1.90×
1.18×
Q3 25
1.41×
1.87×
Q2 25
1.34×
-0.00×
Q1 25
1.44×
1.20×
Q4 24
1.46×
0.35×
Q3 24
1.32×
0.80×
Q2 24
1.48×
-0.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

WST
WST

Proprietary Products$661.8M82%
Contract Manufactured Products$143.2M18%
Affiliated Entity$3.3M0%

WU
WU

Segment breakdown not available.

Related Comparisons